Feasibility of therapy with hypomethylating agents in patients with renal insufficiency

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 3, 2010, Pages 205-210

  Batty, G Nicolas ^a   Kantarjian, Hagop ^a   Issa, Jean Pierre ^a   Jabbour, Elias ^a   Santos, Fabio P S ^a   McCue, Deborah ^a   Garcia Manero, Guillermo ^a   Pierce, Sherry ^a   O'Brien, Susan ^a   Cortés, Jorge E ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Azacitidine; Decitabine; Myelodysplastic syndrome; Serum creatinine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; RETINOIC ACID; TOPOTECAN; VALPROIC ACID; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BONE PAIN; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FOLLOW UP; HUMAN; INFECTION; LIVER DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; OVERALL SURVIVAL; PNEUMONIA; PYREXIA IDIOPATHICA; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; CHRONIC KIDNEY DISEASE; DIALYSIS; FEVER; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; KIDNEY FUNCTION; MYCOSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; DRUG EFFECT; KAPLAN MEIER METHOD; KIDNEY; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RENAL INSUFFICIENCY;

EID: 77955902058     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.032     Document Type: Article

References (15)

1. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20:2429-2440
2. Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional cure regimens (CCR): results of the AZA-001 phase III study. Blood 2007;110:250a (abstract 817).
3. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-1803
4. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52-57
5. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416:552-556
6. Momparler RL, Derse D. Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 1979; 28:1443-1444
7. Chabot GG, Momparler RL. Antileukemic activity of 5-aza-2′- deoxycytidine and cytarabine against intracerebral L1210 murine leukemia. Cancer Treat Rep 1984; 68:1483-1487
8. Lyons J, Bayar E, Fine G, et al. Decitabine: Development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs 2003; 4:1442-1450
9. Marcucci G, Silverman L, Eller M, et al. Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes. J Clin Pharmacol 2005; 45:597.
10. Peterson BA, Collins AJ, Vogelzang NJ, et al. 5-Azacytidine and renal tubular dysfunction. Blood 1981; 57:182-185
11. Aronoff GR, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007.
12. Demirovic JA, et al. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009; 66:642-648
13. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2006; 106:1794-1803
14. Cheson B, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108:419-425
15. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108:3271-3279